AKRO - UPCOMING INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Akero Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AKRO | Benzinga
SAN DIEGO, June 17, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Akero Therapeutics, Inc. (NASDAQ:AKRO) common stock between September 13, 2022 and October 9, 2023, all dates inclusive (the "Class Period"), have until June 25, 2024 to seek appointment as lead plaintiff. Captioned Klobus v. Akero Therapeutics, Inc., No. 3:24-cv-02534 (N.D. Cal.), the Akero class action lawsuit charges Akero as well as certain of its executive officers with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Akero class action lawsuit, please provide your information here:
https://www.rgrdlaw.com/cases-akero-therapeutics-inc-class-action-lawsuit-akro.html
You can also contact attorney J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com. Lead plaintiff motions for the Akero class action lawsuit must be filed with the court no later than June 25, 2024.
CASE ALLEGATIONS: Akero is a clinical stage biopharmaceutical company focused on advancing its lead product candidate efruxifermin ("EFX") to provide a new treatment for patients with nonalcoholic steatohepatitis ("NASH"), a serious liver disease. During the Class Period, Akero claimed to be evaluating EFX in two Phase 2 clinical trials in patients with biopsy-confirmed NASH: (i) Akero's "HARMONY" trial that tested EFX in pre-cirrhotic NASH patients; and (ii) Akero's "SYMMETRY" trial that purportedly tested EFX in patients with NASH-induced cirrhosis.
The Akero class action lawsuit alleges that defendants throughout the Class ...